Cristian Guja

Dr. Cristian Guja

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
SBStephen C. Bain
Stephen C. Bain
OMOfri Mosenzon
Ofri Mosenzon
RARosario Arechavaleta
Rosario Arechavaleta
Paweł BogdańskiPaweł Bogdański
Paweł Bogdański
ACAbdurrahman Comlekci
Abdurrahman Comlekci
MHMansoor Husain
Mansoor Husain
Aim To assess the cardiovascular safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. Methods PIONEER 6 is a multinational, randomised, placebo‐controlled, double‐blind trial in patients with type 2 diabetes (T2D) at high risk of cardiovascular events (defined as being: [1] ≥50 years and having established cardiovascular disease or moderate (Stage 3) chronic kidney disease [CKD], or [2] ≥60 years with ≥1 other cardiovascular risk factor). Patients were randomised to once‐daily oral semaglutide (up to 14 mg) or placebo added to standard of care. The primary composite endpoint is time to first occurrence of cardiovascular death or non‐fatal myocardial infarction or non‐fatal stroke. The primary hypothesis is to rule out an excess in cardiovascular risk with oral semaglutide by assessing non‐inferiority versus placebo for the primary endpoint (non‐inferiority margin of 1.8 for the upper boundary of the 95% confidence interval of the hazard ratio). PIONEER 6 is event‐driven, with follow up continuing until accrual of at least 122 primary outcome events. There is no pre‐defined minimal duration. Results Overall, 3,183 patients have been enrolled (mean age 66.1 years, 31.6% females) in 214 sites across 21 countries. At baseline, the mean duration of diabetes was 14.9 years, mean HbA1c was 8.2%, and 84.6% of patients had established cardiovascular disease/moderate CKD. Conclusions PIONEER 6 will provide evidence regarding the cardiovascular safety of oral semaglutide in patients with T2D and high cardiovascular risk.

6 August 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
SJSerge A. Jabbour
Serge A. Jabbour
JFJuan P. Frías
Juan P. Frías
EHElise Hardy
Elise Hardy
AAAzazuddin Ahmed
Azazuddin Ahmed
HWHui Wang
Hui Wang
CGCristian Guja
Cristian Guja
OBJECTIVE Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than exenatide QW or dapagliflozin alone (DURATION-8). Here, we investigated the safety and maintenance of efficacy at 52 weeks, after a 24-week extension. RESEARCH DESIGN AND METHODS This phase 3, multicenter, double-blind study randomized adults with type 2 diabetes (glycated hemoglobin [HbA1c] 8.0–12.0% [64–108 mmol/mol] on metformin ≥1,500 mg/day) to exenatide QW (2-mg subcutaneous injection) plus once-daily dapagliflozin (10-mg oral tablet), exenatide QW plus oral placebo, or dapagliflozin plus injected placebo. Extension-period P values were nominal. RESULTS Of 1,375 patients screened, 695 were randomized (mean baseline HbA1c 9.3% [78 mmol/mol]); 81.2% completed the study; 75.3% completed treatment. At 52 weeks, HbA1c reductions were greater with exenatide QW plus dapagliflozin (least-squares mean change −1.75% [−19.1 mmol/mol]) versus exenatide QW (−1.38% [−15.1 mmol/mol]; P = 0.006) or dapagliflozin (−1.23% [−13.4 mmol/mol]; P < 0.001); mean HbA1c values were 6.9% (52 mmol/mol), 7.2% (55 mmol/mol), and 7.4% (57 mmol/mol), respectively. Weight and SBP reductions were greater with exenatide QW plus dapagliflozin (−3.31 kg and −4.5 mmHg) versus exenatide QW (−1.51 kg and −0.7 mmHg; both P < 0.001) but similar to those with dapagliflozin (−2.28 kg and −2.7 mmHg; P = 0.057 and P = 0.100, respectively). The exenatide QW plus dapagliflozin regimen was well tolerated with no unexpected safety findings; more patients treated with exenatide QW experienced gastrointestinal and injection site–related adverse events. No major hypoglycemia occurred. CONCLUSIONS Among patients with type 2 diabetes uncontrolled with metformin, exenatide QW plus dapagliflozin provided sustained improvements in glycemia, weight, and SBP over 52 weeks, with no unexpected safety findings.

6 November 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
Amalia GastaldelliAmalia Gastaldelli
Amalia Gastaldelli
EREnrico Repetto
Enrico Repetto
CGCristian Guja
Cristian Guja
EHElise Hardy
Elise Hardy
JHJenny Han
Jenny Han
EFEle Ferrannini
Ele Ferrannini
Aim: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION‐8, a 104‐week study in 695 patients with type 2 diabetes uncontrolled by metformin monotherapy. Materials and methods: We evaluated the impact of the study treatments on non‐invasive markers of hepatic steatosis (fatty liver index [FLI] and non‐alcoholic fatty liver disease [NAFLD] liver fat score), fibrosis (fibrosis‐4 index [FIB‐4]) and severe fibrosis (NAFLD fibrosis score), along with liver enzymes and insulin resistance, at weeks 28 and 52. All outcomes in this analysis were exploratory, with nominal P values reported. Results: At week 28, biomarkers of fatty liver/steatosis and fibrosis were reduced from baseline in all treatment groups. At week 28, EXE once weekly + DAPA effects for decrease in FLI were stronger than those of EXE once weekly + placebo (PLB; −2.92, 95% confidence interval [CI] −5.11, −0.73; P = 0.0092) or DAPA+PLB (−2.77 [95% CI −4.93, −0.62]; P = 0.0119), and stronger than those of EXE once weekly + PLB at week 52 (−3.23 [95% CI −5.79, −0.68]; P = 0.0134). FIB‐4 showed reduction versus baseline only in the EXE once weekly + DAPA group at both week 28 (−0.06 [95% CI −0.11, −0.01]; P = 0.0135) and week 52 (−0.05 [95% CI −0.09, −0.004]; P = 0.0308). Conclusions: The EXE once weekly + DAPA combination showed stronger effects than EXE once weekly + PLB or DAPA + PLB in ameliorating markers of hepatic steatosis and fibrosis in patients with type 2 diabetes. Prospective trials are needed to validate these findings.

25 March 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
CGCristian Guja
Cristian Guja
JFJuan P. Frías
Juan P. Frías
ASAniko Somogyi
Aniko Somogyi
SJSerge A. Jabbour
Serge A. Jabbour
HWHui Wang
Hui Wang
JRJulio Rosenstock
Julio Rosenstock
Aims: To compare the efficacy and safety of adding the glucagon‐like peptide‐1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin. Methods: This multicentre, double‐blind study ( ClinicalTrials.gov identifier: NCT02229383) randomized (1:1) patients with persistent hyperglycaemia after an 8‐week titration phase (glycated haemoglobin [HbA1c] 7.0%‐10.5% [53‐91 mmol/mol]) to exenatide QW or placebo. The primary endpoint was HbA1c change from baseline to week 28. Secondary endpoints included body weight, 2‐hour postprandial glucose, and mean daily IG dose. Results: Of 464 randomized patients (mean: age, 58 years; HbA1c, 8.5% [69 mmol/mol]; diabetes duration, 11.3 years), 91% completed 28 weeks. Exenatide QW + IG vs placebo + IG significantly reduced HbA1c (least‐squares mean difference, −0.73% [−8.0 mmol/mol]; 95% confidence interval, −0.93%, −0.53% [−10.2, −5.8 mmol/mol]; P < .001; final HbA1c, 7.55% [59 mmol/mol] and 8.24% [67 mmol/mol], respectively); body weight (−1.50 kg; −2.17, −0.84; P < .001); and 2‐hour postprandial glucose (−1.52 mmol/L [−27.5 mg/dL]; −2.15, −0.90 [−38.7, −16.2]; P < .001). Significantly more exenatide QW + IG‐treated patients vs placebo + IG‐treated patients reached HbA1c <7.0% (<53 mmol/mol) (32.5% vs 7.4%; P < .001); daily IG dose increased by 2 and 4 units, respectively. Gastrointestinal and injection‐site adverse events were more frequent with exenatide QW + IG (15.1% and 7.8%, respectively) than with placebo + IG (10.8% and 3.0%, respectively); hypoglycaemia incidence was similar between the exenatide QW + IG (29.7%) and placebo + IG (29.0%) groups, with no major hypoglycaemic events. Conclusions: Among patients with inadequate glycaemic control, exenatide QW significantly improved glucose control and decreased body weight, without increased hypoglycaemia or unexpected safety findings.

18 August 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
SJSerge A. Jabbour
Serge A. Jabbour
JFJuan P. Frías
Juan P. Frías
AAAzazuddin Ahmed
Azazuddin Ahmed
EHElise Hardy
Elise Hardy
JCJasmine Choi
Jasmine Choi
CGCristian Guja
Cristian Guja
OBJECTIVE In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0–12.0% [64–108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (−1.70% [0.11]) versus exenatide QW plus placebo (−1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (−1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.

4 February 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
SJSerge A. Jabbour
Serge A. Jabbour
JFJuan P. Frías
Juan P. Frías
CGCristian Guja
Cristian Guja
EHElise Hardy
Elise Hardy
AAAzazuddin Ahmed
Azazuddin Ahmed
PÖPeter Öhman
Peter Öhman
This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks’ treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION‐8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels. Body weight, SBP and triglyceride levels were reduced across most respective subgroups, with no significant subgroup‐by‐treatment interactions. For each treatment, weight loss was numerically greater as baseline body mass index increased. SBP reductions were greater among patients with SBP ≥140 vs <140 mm Hg for exenatide once weekly plus dapagliflozin and exenatide once weekly. Reductions in triglyceride levels were greater among patients with baseline triglycerides <1.69 vs ≥1.69 mmol/L for each treatment. The combination of exenatide once weekly plus dapagliflozin reduced cardiovascular risk factors across baseline subgroups for each variable to a greater extent than did either individual drug; the greatest effects were observed in the high baseline subgroups for body weight and SBP.